Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Research study investigates survival rates of prostate cancer patients across time periods

New research to be published in tomorrow's issue of the Journal of the American Medical Association (JAMA) (Vol. 302, No. 11), by a team at The Cancer Institute of New Jersey (CINJ), shows that men diagnosed with prostate cancer beginning in the early 1990's had significantly improved survival outcomes compared with patients whose cancers were diagnosed in prior decades.

16 Sep 2009

Sudden Cardiac Arrest Foundation launches second video awareness contest on YouTube

To celebrate National Sudden Cardiac Arrest Awareness Month in October, the Sudden Cardiac Arrest Foundation today announced the launch of its second 'You Can Save a Life(TM)' video awareness contest on YouTube.

16 Sep 2009

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed.

16 Sep 2009

Researchers analyze how genome influences human health

Two recent studies by Dartmouth researchers use individual genetic data to reveal the powers and limits of our current understanding of how the genome influences human health and what genes can reveal about the ancestry of the people of New Hampshire.

15 Sep 2009

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

In light of the economy and rising unemployment, people are looking to cut costs wherever they can. As the costs of many surgeries and procedures continue to rise in the US, many are looking for cheaper alternatives abroad. This big business is known as "medical tourism," and often promises healthcare options at a fraction of the cost as in the United States. However, this is one area where bargain shopping is not recommended, counsels Dr. David B. Samadi, Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

15 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

15 Sep 2009

Calypso’s GPS for the Body technology installed at University Of Maryland Greenebaum Cancer Center

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, announced today that the University of Maryland Marlene and Stewart Greenebaum Cancer Center, a National Cancer Institute-designated cancer center in Baltimore, now offers the Calypso® System to provide accurate, precise, real-time tumor tracking for cancer patients undergoing external beam radiation therapy.

14 Sep 2009

Men and healthcare professionals urged to take proactive approach to prostate cancer

As prostate cancer is the third leading cause of cancer death in European men with more than 300,000 men being diagnosed every year, society needs to commit to changing the way the disease is viewed. Therefore a mini-symposium and lunch meeting are organized on 18 September 2009 in Antwerp on the occasion of the European launch of the Proactive Prostates Initiative, organized as part of Urology Week.

14 Sep 2009

GENova to file for Prostaganin patents in the US and in Europe

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

14 Sep 2009

GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer

GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.

14 Sep 2009

Urodynamix Technologies raises funds through private placement

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it is raising a minimum of $1,500,000 through the issuance of 30,000,000 common shares of the Company at a price of $0.05 per common share. BC Advantage Funds has provided the Company with a lead order of $750,000.

14 Sep 2009

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Teva Pharmaceutical Industries Ltd. and Active Biotech today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties.

14 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

Body mass in younger and older adulthood linked to prostate cancer risks

A team of scientists led by researcher Brenda Hernandez, Ph.D., M.P.H.-an assistant professor at the University of Hawai'i at Mānoa's Cancer Research Center of Hawai'i-has reported that body mass in younger and older adulthood, and weight gain between these life periods, may influence a man's risk for prostate cancer. This risk varies among different ethnic groups, according to findings reported in a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

14 Sep 2009

Obama's interview on health and fitness priorities to be published in a health magazine

President Barack Obama and First Lady Michelle Obama speak candidly about health and fitness priorities for the country and their family in exclusive interviews that will appear in the October 2009 issues of Men’s Health and Women’s Health, respectively. The October issues hit newsstands on Tuesday, September 15.

14 Sep 2009

Genspera to commence G-202 Phase I trial following FDA approval

GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer.

11 Sep 2009

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

GENova Biotherapeutics to obtain three new drug target patents

GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

11 Sep 2009

Fau and MELK genes may help improve breast cancer diagnosis and treatment

Researchers at Keele University have identified two genes which may help improve the diagnosis and treatment of breast cancer patients.

11 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Research study investigates survival rates of prostate cancer patients across time periods

Sudden Cardiac Arrest Foundation launches second video awareness contest on YouTube

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

Researchers analyze how genome influences human health

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

Third-quarter fiscal 2009 results announced by DiagnoCure

Calypso’s GPS for the Body technology installed at University Of Maryland Greenebaum Cancer Center

Men and healthcare professionals urged to take proactive approach to prostate cancer

GENova to file for Prostaganin patents in the US and in Europe

GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer

Urodynamix Technologies raises funds through private placement

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Body mass in younger and older adulthood linked to prostate cancer risks

Obama's interview on health and fitness priorities to be published in a health magazine

Genspera to commence G-202 Phase I trial following FDA approval

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

GENova Biotherapeutics to obtain three new drug target patents

Fau and MELK genes may help improve breast cancer diagnosis and treatment

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in